© 2021 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
All Articles
Treatment with voretigene neparvovec-rzyl results in foveal morphologic changes in LCA
May 10, 2021
In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
Injections offer relief for refractory severe noninfectious keratitis
May 07, 2021
Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.
Diabetes and DR: Making progress in the global epidemic
May 05, 2021
During a presentation at the ARVO virtual meeting, Lloyd Paul Aiello, MD, PhD, explains that a key hurdle for diabetic retinopathy is the lack of patient awareness, which is a substantial contributor to non-adherence to eye care guidelines and poor outcomes.
Initial data from AGTC-501 subretinal gene therapy for X-linked RP demonstrates safety, efficacy
May 05, 2021
During an ARVO presentation, Paul Yang, MD, PhD, explained that in a clinical trial, investigators used an adeno-associated viral vector to deliver a normal functioning copy of the RPGR gene via subretinal injection.
AI enhances customised myopic LASIK with ray tracing optimisation
May 05, 2021
Customised myopic LASIK using automated ray tracing optimisation has the potential to offer improved and more predictable outcomes, a study shows.
Non-viral gene therapy eases treatment burden in wet AMD
May 03, 2021
EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.
Corneal crosslinking outcomes appear to justify its use in paediatrics
May 03, 2021
Studies show that corneal crosslinking could be a beneficial treatment in paediatric patients with keratoconus.
TENAYA, LUCERNE trials show faricimab reaches primary endpoints
May 03, 2021
Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.
Research focuses on use of intravitreal injection of allogeneic human retinal progenitor cells to treat RP
May 01, 2021
According to Sunil Srivastava, MD, optical coherence tomography characteristics may be predictive of the efficacy of the injections.
Investigators offer positive results in treatment of DME with faricimab
May 01, 2021
During ARVO’s 2021 virtual annual meeting, John Wells, MD, presented efficacy, durability, and safety findings from phase 3 YOSEMITE and RHINE trials.